About Cardior Pharmaceuticals
Cardior Pharmaceuticals is a company based in Hannover (Germany) founded in 2016 was acquired by Novo Nordisk in March 2024.. Cardior Pharmaceuticals has raised $92.32 million across 3 funding rounds from investors including Novo Nordisk, European Union and Bristol-Myers Squibb. Cardior Pharmaceuticals operates in a competitive market with competitors including MiRagen, Portola Pharma, Cellino, Arrakis Therapeutics and Tenaya Therapeutics, among others.
- Headquarter Hannover, Germany
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
$86.77 K (USD)164as on Dec 31, 2019
-
Net Profit
$-5.89 M (USD)5as on Dec 31, 2019
-
EBITDA
-
Total Equity Funding
$92.32 M (USD)
in 3 rounds
-
Latest Funding Round
$76 M (USD), Series B
Aug 25, 2021
-
Investors
Novo Nordisk
& 11 more
-
Employee Count
Employee Count
-
Acquired by
Novo Nordisk
(Mar 25, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of Cardior Pharmaceuticals
Cardior Pharmaceuticals has successfully raised a total of $92.32M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $76 million completed in August 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $76.0M
-
First Round
First Round
(11 May 2017)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2021 | Amount | Series B - Cardior Pharmaceuticals | Valuation | Inkef | |
| Jan, 2019 | Amount | Grant - Cardior Pharmaceuticals | Valuation |
investors |
|
| May, 2017 | Amount | Series A - Cardior Pharmaceuticals | Valuation | Life Sciences Partners , Boehringer Ingelheim Venture Fund |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Cardior Pharmaceuticals
Cardior Pharmaceuticals has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Novo Nordisk, European Union and Bristol-Myers Squibb. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Fund+ is focused on investing in life sciences companies.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Venture capital funding for young German technology companies.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Cardior Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Cardior Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cardior Pharmaceuticals Comparisons
Competitors of Cardior Pharmaceuticals
Cardior Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MiRagen, Portola Pharma, Cellino, Arrakis Therapeutics and Tenaya Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cardiovascular and autoimmune diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of autologous cell therapies
|
|
| domain | founded_year | HQ Location |
Provider of tools for the analysis of RNA structures
|
|
| domain | founded_year | HQ Location |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| domain | founded_year | HQ Location |
Innovative pharmaceuticals for cardiovascular and metabolic diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cardior Pharmaceuticals
Frequently Asked Questions about Cardior Pharmaceuticals
When was Cardior Pharmaceuticals founded?
Cardior Pharmaceuticals was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Where is Cardior Pharmaceuticals located?
Cardior Pharmaceuticals is headquartered in Hannover, Germany. It is registered at Hannover, Niedersachsen, Germany.
Is Cardior Pharmaceuticals a funded company?
Cardior Pharmaceuticals is a funded company, having raised a total of $92.32M across 3 funding rounds to date. The company's 1st funding round was a Series A of $16.32M, raised on May 11, 2017.
What is the annual revenue of Cardior Pharmaceuticals?
Annual revenue of Cardior Pharmaceuticals is $86.77K as on Dec 31, 2019.
What does Cardior Pharmaceuticals do?
Cardior Pharmaceuticals was founded in 2016 in Hannover, Germany, within the biotechnology sector. Focus is placed on developing therapeutics based on non-coding RNA to address cardiovascular diseases, particularly heart failure. Oligonucleotide-based inhibitors are utilized to target non-coding RNAs that regulate cardiac growth, calcium handling, and cardiomyocyte contractility. Operations center on advancing these molecular interventions for clinical applications.
Who are the top competitors of Cardior Pharmaceuticals?
Cardior Pharmaceuticals's top competitors include Tenaya Therapeutics, Cellino and MyoKardia.
Who are Cardior Pharmaceuticals's investors?
Cardior Pharmaceuticals has 12 investors. Key investors include Novo Nordisk, European Union, Bristol-Myers Squibb, Life Sciences Partners, and Fund+.